Immunomodulators, including certain immune checkpoint inhibitors (such as PD-1 and CTLA-4 inhibitors), have been incorporated into ADCs designs to enhance immune responses within the tumor microenvironment (70, 71). This evidence concerns the gene CTLA4 and neoplasm.